We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 770

Bribery Act - Germany gets ready for stricter criminal laws
  • Taylor Wessing
  • Germany, United Kingdom
  • March 17 2015

In its cabinet session on 21 January 2015, the German government adopted the draft bill on combating corruption of the Ministry of Justice and

Los genéricos y las empresas que les suministran: nueva cuestión prejudicial
  • Abril Abogados
  • European Union, Germany
  • February 22 2014

El tribunal superior de justicia de Dusseldorf (Alemania) ha elevado cuestion prejudicial al Tribunal de Justicia sobre la relacion

German Federal Supreme Court on whether therapy-related instructions may contribute to patentability in case of a claim directed to a substance for use in therapeutic treatment (decisions of February 25, 2014 Cases X ZB 513 and X ZB 613 Collagenase
  • BARDEHLE PAGENBERG Partnerschaft mbB
  • Germany
  • July 14 2014

Therapy-related instructions ("therapiebezogene Anweisungen") may contribute to patentability if they objectively aim at allowing, enhancing

Connected health: legal aspects of health apps in Germany
  • Taylor Wessing
  • Germany
  • April 20 2015

In the near future, your smartphone may act as a "portable GP": Analysing the data from a wireless sensor patch on your body to warn you about your

Investing in healthcare facilities in Germany - ten things to know
  • Norton Rose Fulbright LLP
  • Germany
  • November 24 2014

Well managed healthcare facilities create steady cash flows and reasonably high margins. However, many owners of healthcare facilities are no longer

International news: focus on compliance - winter 2014
  • McDermott Will & Emery
  • China, European Union, Germany, Global, USA
  • December 2 2014

As regulatory oversight of companiesfrom Sarbanes Oxley and the Dodd-Frank Act to the Foreign Corrupt Practices Act (FCPA) and the UK Bribery

Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?
  • Bryan Cave LLP
  • European Union, France, Germany, Italy, United Kingdom
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the

FSC decides on patentability of neural progenitor cells II (Brustle)
  • Bird & Bird
  • Germany
  • February 25 2013

Recently, the German Federal Supreme Court decided on a nullity action on the patentability of progenitor cells extracted from human embryonic stem

Update on recent case law restricting advertising of medicinal products
  • Baker & McKenzie
  • Germany
  • February 6 2015

Recent court decisions confirm the rigorous standard ("Strengeprinzip") applied by German courts when analyzing whether or not health claims in

Germany - unhealthy showdown
  • Freshfields Bruckhaus Deringer LLP
  • Germany
  • July 5 2013

The German government has signalled its intention to fight corruption in the healthcare sector before its current term of office comes to an end